Quantitative Imaging for Assessing Breast Cancer Response to Treatment

1. Quantitative Imaging for Assessing Breast Cancer Response to Treatment University of California, San Francisco Ella Jones, Lisa Wilmes, David Newitt, Sheye Aliu and Nola Hylton Research Goal 1: To develop QC procedures for breast DWI to be implemented in ISPY2/ACRIN 6698 Collaboration with Katy Keenan, NIST UCSF Investigators: Sheye Aliu, Lisa Wilmes, David Newitt, Ella Jones ACRIN 6698 Quality and Usability I-SPY2 / ACRIN 6698 Workflow • Multiple PVP Diffusion Values • Resolution/distortion plates • Multiple T1 / T2 Values • Alternating Fat / Tissue Mimics PVP = polyvinylpyrrolidone PVP concentration corresponds to 4%,10%, 14%, 18%, 25% and 40% in water to mimic normal, benign and malignant tissues ACRIN 6698 DW-MRI optional at inter-regimen and pre-surgical time points Research Goal 3: To facilitate secondary analyses and promote integrated imaging in I-SPY by providing cleaned, annotated QI data ACRIN 6698 DWI Quality Control Quality Usability • QIN and ACRIN support to build and provide: • Hierarchical QI datasets and data dictionary • Radiologist assessed (BIRADS) and computer-generated measurements • Integrated AIM compatibility and annotations (collaboration with Daniel Rubin, Stanford QIN) • Access through TCIA (I-SPY-1) and NBIA (I-SPY-2) • Streamlined data access requests through ACRIN and I-SPY Developed by Sheye Aliu, Tom Chenevert and 6698 Technical Team Research Goal 2: To develop a universal breast MRI phantom with NIST for use in multi-center trials (Collaboration with Katy Keenan, NIST) Image quality assessment • Protocol compliant images are evaluated • Artifacts, Fat Suppression and Signal-to-Noise are ranked AA through FF (AA=4.0, AB=3.5, BB=3.0, …, FF=0) • Overall Score is average of rankings Ex: (3.5+2.0+0.5)/3 Image usability assessment • High: Overall Score > 1 and no ADC artifacts • Moderate: Overall Score > 1 but ADC artifacts • Low: Overall Score <= 1 or excessive ADC artifacts Universal Breast MRI Phantom Deliverables • Developed breast DWI QC protocols • Completed test-re-test repeatability study data analysis • Completed first generation universal breast phantom prototype design • Presented the repeatability study of normal subjects at the WMIC and submitted for publication in Translational Oncology • Submitted validation of the Aegis SER software platform study for publication in Translational Oncology • Submitted abstracts for findings from gradient nonlinearity correction and breast phantom studies to the 2014 ISMRM